Possible New Key to Parkinson’s Treatment

Date
Author
Parkinson's Foundation

All Science News articles summarize a research study and are not an official opinion, endorsement or position of the Parkinson’s Foundation’s.

In 10 percent of people with Parkinson's disease (PD), the disease is familial (tied to genetics), while the other 90 percent are nonfamilial. Mutations in the LRRK2 gene are the most common cause of familial PD. In fact, researchers have identified more than 100 LRRK2 gene mutations in families with PD. 

Category
Science News

What's Hot in PD?: What Are the Disease Modifying Therapies in Trial for Parkinson’s Disease?

Date
Author
Dr. Michael S. Okun

We always advise patients to ask their doctor what’s new in Parkinson’s disease (PD). Recently, three leading experts at the Parkinson’s Foundation Center Leadership Conference reviewed the field and updated all attendees on several of the exciting therapies currently being tested by Albert Hung, MD, PhD, Massachusetts General Hospital (MGH); Irene Richard, MD, University of Rochester Medical Center; and Hubert Fernandez, MD, Cleveland Clinic. In this month’s What’s Hot in PD blog we review their latest therapies.

Category
What's Hot in PD?

Key Enzyme Regulates Brain Cell Change in Parkinson’s

Date
Author
Parkinson's Foundation

In studies with laboratory mice, scientists have identified a single molecule, an enzyme called c-Abl, that regulates the build-up of toxic alpha-synuclein protein in brain cells. Such protein clumps, known as Lewy bodies, are the hallmark of Parkinson’s disease (PD). The finding suggests that blocking the enzyme may be an effective approach for new therapies to treat PD. The research appears in the June 27 online edition of The Journal of Clinical Investigation.

Category
Science News

Cancer Drug Shows Evidence of Safety for Parkinson’s

Date
Author
Parkinson's Foundation

Nilotinib, a drug already approved for treatment of leukemia and with potential for treating Parkinson’s disease (PD) may be safe to use experimentally in PD, according to the results of a small, phase 1 clinical trial. The study appears in the July 11 online edition of the Journal of Parkinson’s Disease.

Category
Science News

What's Hot in PD? What Led Scientists to Believe a Cancer Drug Could Treat Parkinson’s?

Date
Author
Dr. Michael S. Okun

The recent media blitz about a leukemia drug named Nilotinib as a potential treatment for Parkinson’s disease resulted in thousands of patients and family members phoning their doctors and our 1-800-4PD-INFO Helpline requesting access to this drug. The Parkinson's Foundation quickly responded with a public statement recommending that patients not pursue this therapy unless under a clinical trial. There were serious concerns about the size and methodology of this initial report which was recently presented at the Society for Neuroscience meeting.

Category
What's Hot in PD?

What's Hot in PD? Nilotinib and Repurposing Other Drugs to Treat Parkinson’s Disease

Date
Author
Dr. Michael S. Okun

What if I told you that it was possible that existing and already FDA-approved drugs could possibly be breakthrough treatments for Parkinson’s disease (PD)? It is an exciting potential reality. Our Center of Excellence at Georgetown University has been exploring one such compound, which has been previously used as an anti-cancer drug. The drug is actually already FDA approved to address chronic myelogenous leukemia.

Category
What's Hot in PD?

mail icon

Subscribe here to get the latest news on treatments, research and other updates.